FDA approves expansion to Orchestra BioMed pacemaker trial
August 8, 2025
Orchestra BioMed (Nasdaq:OBIO) announced today that it began the rollout of a protocol update for its BACKBEAT study.
Orchestra BioMed (Nasdaq:OBIO) announced today that it began the rollout of a protocol update for its BACKBEAT study.
Nyxoah (Nasdaq:NYXH) announced today that it received FDA approval for its Genio neuromodulation device for treating sleep apnea.
A study led by Roswell Park Comprehensive Cancer Center helps explain why a rare and hyper-aggressive subtype of kidney cancer is susceptible to immunotherapy—information that helped researchers create a first-of-its-kind tool to guide treatment decisions for advanced kidney cancers.
A mobile phone app designed to deliver suicide-specific therapy reduced suicidal behavior among high-risk psychiatric inpatients, according to a new study by scientists at Yale School of Medicine and The Ohio State University Wexner Medical Center and College of Medicine.
The introduction of the test is underpinned by data from the blinded, prospective EXPAND study, which began in 2023.
Under PreCheck, the FDA will communicate more frequently with pharmaceutical companies, helping them as they establish or expand manufacturing sites in the U.S.
Founded in 2009, QinFlow is a market leader in fluid thermoregulation solutions.
The diagnostic performance of HyCoSy with SF6 microbubbles claims to have been validated by a meta-analysis of 24 trials.
Heart attacks remain a leading cause of death and disability worldwide. The permanent loss of heart muscle cells—known as cardiomyocytes—and the heart’s limited regenerative capacity often lead to chronic heart failure. Current treatment strategies manage symptoms but do not repair the underlying damage.
In a first-of-its-kind clinical trial, UCLA scientists have shown it’s possible to reprogram a patient’s blood-forming stem cells to generate a continuous supply of functional T cells, the immune system’s most powerful cancer-killing agents.